NRAS and acute myeloid leukemia: Large datasets have found mutations in additional genes (including IDH1/2, DNMT3A, RUNX1, TET2, NRAS, MLL, and others) to confer adverse prognosis, but it remains unclear how modifications to treatment regimens or the use of stem cell transplantation will impact outcomes in these specific subtypes of AML.